Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CYTX

Cytori Therapeutics (CYTX) Stock Price, News & Analysis

Cytori Therapeutics logo

About Cytori Therapeutics Stock (NASDAQ:CYTX)

Advanced Chart

Key Stats

Today's Range
$0.33
$0.36
50-Day Range
$0.20
$0.21
52-Week Range
$0.20
$0.75
Volume
6.56 million shs
Average Volume
915,302 shs
Market Capitalization
$7.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CYTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytori Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYTX Stock News Headlines

Cytori Cell Research Institute Inc.
Checkpoint Therapeutics Inc (CKPT)
A new rule goes live in July — and the banks are quietly cashing in
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.
Sage Therapeutics Inc SAGE
5 Biotech Stocks Under $10 Blasting Higher
8 Stocks Under $10 Ripping Higher
See More Headlines

CYTX Stock Analysis - Frequently Asked Questions

Cytori Therapeutics Inc (NASDAQ:CYTX) issued its quarterly earnings data on Tuesday, May, 14th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.02. The biotechnology company earned $0.70 million during the quarter. Cytori Therapeutics had a negative trailing twelve-month return on equity of 272.70% and a negative net margin of 242.60%.

Cytori Therapeutics shares reverse split before market open on Thursday, May 24th 2018.The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Bank of America (BAC), BCE (BCE), Celldex Therapeutics (CLDX) and Micron Technology (MU).

Company Calendar

Last Earnings
5/14/2019
Today
7/14/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CYTX
CIK
1095981
Fax
N/A
Employees
37
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.63 million
Net Margins
-242.60%
Pretax Margin
N/A
Return on Equity
-272.70%
Return on Assets
-56.23%

Debt

Debt-to-Equity Ratio
0.39
Current Ratio
0.46
Quick Ratio
0.30

Sales & Book Value

Annual Sales
$3.67 million
Price / Sales
2.17
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
1.03

Miscellaneous

Outstanding Shares
22,160,000
Free Float
N/A
Market Cap
$7.97 million
Optionable
Not Optionable
Beta
1.96
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:CYTX) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners